Should a BRCA2 stop codon human variant, usually considered a polymorphism, be classified as a predisposing mutation?

Author： D'Argenio Valeria   Esposito Maria Valeria   Gilder Jean Ann   Frisso Giulia   Salvatore Francesco  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|10|1594-1595

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.10, 2014-05, pp. : 1594-1595

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

How should P 2X purinoceptors be classified pharmacologically?

By Kennedy C.   Leff P.  

Trends in Pharmacological Sciences, Vol. 16, Iss. 5, 1995-05 ,pp. : 168-174

Elsevier

Access to resources Recommend Favorite

Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?

By  

Current Pharmacogenomics, Vol. 5, Iss. 4, 2007-12 ,pp. : 280-291

Bentham Science Publishers

Access to resources Recommend Favorite

Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers

By Domchek Susan M.   Stopfer Jill E.   Rebbeck Timothy R.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 2, 2006-02 ,pp. : 177-182

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition

By Vidarsdottir Linda  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 425-434

Springer Publishing Company

Access to resources Recommend Favorite

Magnesium sulfate tocolysis should stop

By  

Reactions Weekly, Vol. 1, Iss. 1124, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite